Sentences with phrase «commissions on common stock»

Dividend Reinvestment Programs (DRIP) are one way to avoid paying trade commissions on common stock purchases.

Not exact matches

Other than the underwriting discount described on the front cover of this prospectus, the underwriters will not be entitled to any commission with respect to shares of common stock sold pursuant to the directed share program.

We estimate that we will receive net proceeds from this offering of $ billion based on an assumed initial public offering price of $ per share of Class A common stock, the midpoint of the estimated price range set forth on the cover page of this prospectus, after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us.

Subject to the terms and conditions of the underwriting agreement, the underwriters named below, through their representatives Barclays Capital Inc. and Deutsche Bank Securities Inc., have severally agreed to purchase from us the following respective number of shares of common stock at a public offering price less the underwriting discounts and commissions set forth on the cover of this prospectus:

on a pro forma as adjusted basis to reflect the receipt by us of estimated net proceeds of $ million from the sale of shares of common stock offered by us at an assumed initial offering price of $ per share, which is the midpoint of the range listed on the cover page of this prospectus, after deducting the estimated underwriting discounts and commissions and offering expenses payable by us.

As long as PS Fund (along with any of its Related Persons) does not otherwise engage in (or has not otherwise engaged in) conduct that would otherwise result in its becoming an Acquiring Person by becoming the Beneficial Owner of 10 % or more of the shares of Common Stock then outstanding, PS Fund's solicitation and receipt of one or more revocable proxies from the Company's stockholders to be counted toward the number of shares of the outstanding Common Stock needed to cause a special meeting of stockholders to be called pursuant to and in accordance with the Bylaws, which proxies are given to PS Fund in response to a public solicitation of proxies made pursuant to, and in accordance with, Section 14 (a) of the Exchnage Act by means of a solicitation statement filed with the Commission on Schedule 15A, should not, of itself, cause PS Fund to become an Acquiring Person.

The distribution of Marriott Vacations Worldwide common stock is subject to the satisfaction or waiver of certain conditions including but not limited to the Registration Statement on Form 10 for Marriott Vacations Worldwide common stock being declared effective by the U.S. Securities and Exchange Commission, Marriott Vacations Worldwide common stock being accepted for listing on the NYSE and the other conditions described in the Information Statement included in the Form 10.

LF - RB Management, LLC and certain shareholders named below (referred to as the «LF - RB Group»), which beneficially own an aggregate of 952,569 shares of the common stock of RiceBran Technologies (RIBT), filed definitive proxy materials with the Securities and Exchange Commission (the «SEC») on June 13, 2016, available at www.sec.gov.

These risks and uncertainties include, among others, those relating to our ability to obtain sufficient financing to continue as a going concern, the outcome of the review of the continued listing of our common stock on The Nasdaq Stock Market, our ability to develop and market diagnostic products, the level of third party reimbursement for our products, risks related to preclinical and clinical development of pharmaceutical products, including the identification of compounds and the completion of clinical trials, our ability to form collaborative relationships, the effect of government regulation and the regulatory approval processes, market acceptance, our ability to obtain and protect intellectual property rights for our products, dependence on collaborative relationships, the effect of competitive products, industry trends and other risks identified in deCODE's filings with the Securities and Exchange Commission, including, without limitation, the risk factors identified in our most recent Annual Report on Form 10 - K and any updates to those risk factors filed from time to time in our Quarterly Reports on Form 10 - Q or Current Reports on Form 8stock on The Nasdaq Stock Market, our ability to develop and market diagnostic products, the level of third party reimbursement for our products, risks related to preclinical and clinical development of pharmaceutical products, including the identification of compounds and the completion of clinical trials, our ability to form collaborative relationships, the effect of government regulation and the regulatory approval processes, market acceptance, our ability to obtain and protect intellectual property rights for our products, dependence on collaborative relationships, the effect of competitive products, industry trends and other risks identified in deCODE's filings with the Securities and Exchange Commission, including, without limitation, the risk factors identified in our most recent Annual Report on Form 10 - K and any updates to those risk factors filed from time to time in our Quarterly Reports on Form 10 - Q or Current Reports on Form 8Stock Market, our ability to develop and market diagnostic products, the level of third party reimbursement for our products, risks related to preclinical and clinical development of pharmaceutical products, including the identification of compounds and the completion of clinical trials, our ability to form collaborative relationships, the effect of government regulation and the regulatory approval processes, market acceptance, our ability to obtain and protect intellectual property rights for our products, dependence on collaborative relationships, the effect of competitive products, industry trends and other risks identified in deCODE's filings with the Securities and Exchange Commission, including, without limitation, the risk factors identified in our most recent Annual Report on Form 10 - K and any updates to those risk factors filed from time to time in our Quarterly Reports on Form 10 - Q or Current Reports on Form 8 - K.

• on August 19, 2009, the NASDAQ Stock Market announced that it will delist the Company's common stock (NASDAQ will file a Form 25 with the Commission to complete the delisting which becomes effective ten days after the Form 25 is filed)Stock Market announced that it will delist the Company's common stock (NASDAQ will file a Form 25 with the Commission to complete the delisting which becomes effective ten days after the Form 25 is filed)stock (NASDAQ will file a Form 25 with the Commission to complete the delisting which becomes effective ten days after the Form 25 is filed); and

Also remember that the commissions on preferred stocks are roughly equivalent to those on common stock.

In this Quarterly Report on Form 10 - Q, unless the context otherwise requires, the following terms have the meanings assigned to them as set forth below: «we», «our», and the «Company» refer to Forward Industries, Inc., a New York corporation, together with its consolidated subsidiaries; «Forward» or «Forward Industries» refers to Forward Industries, Inc.; «common stock» refers to the common stock, $.01 par value per share, of Forward Industries, Inc.; «Koszegi» refers to Forward Industries» wholly owned subsidiary Koszegi Industries, Inc., an Indiana corporation; «Forward HK» refers to Forward Industries» wholly owned subsidiary Forward Industries HK, Ltd., a Hong Kong corporation; «Forward Innovations» refers to Forward Industries» wholly owned subsidiary Forward Innovations GmbH, a Swiss corporation; «Forward APAC» refers to Forward Industries» wholly owned subsidiary Forward Asia Pacific Limited, a Hong Kong corporation; «GAAP» refers to accounting principles generally accepted in the United States; «Commission» refers to the United States Securities and Exchange Commission; «Exchange Act» refers to the United States Securities Exchange Act of 1934, as amended;

In addition, the Company's common stock (the «Common Stock») was officially delisted from the NASDAQ Global Market at the opening of trading on the Effective Date, pursuant to the previously filed Form 25, which the Company filed with the Securities and Exchange Commission and The NASDAQ Stock Market, Inc. on June 22,common stock (the «Common Stock») was officially delisted from the NASDAQ Global Market at the opening of trading on the Effective Date, pursuant to the previously filed Form 25, which the Company filed with the Securities and Exchange Commission and The NASDAQ Stock Market, Inc. on June 22, stock (the «Common Stock») was officially delisted from the NASDAQ Global Market at the opening of trading on the Effective Date, pursuant to the previously filed Form 25, which the Company filed with the Securities and Exchange Commission and The NASDAQ Stock Market, Inc. on June 22,Common Stock») was officially delisted from the NASDAQ Global Market at the opening of trading on the Effective Date, pursuant to the previously filed Form 25, which the Company filed with the Securities and Exchange Commission and The NASDAQ Stock Market, Inc. on June 22, Stock») was officially delisted from the NASDAQ Global Market at the opening of trading on the Effective Date, pursuant to the previously filed Form 25, which the Company filed with the Securities and Exchange Commission and The NASDAQ Stock Market, Inc. on June 22, Stock Market, Inc. on June 22, 2009.

We understand that MediciNova, Inc., a Delaware corporation, (the «Offeror») has made a non-binding, publicly disclosed offer (the «Offer») to acquire, pursuant to a proposed merger transaction, all of the issued and outstanding shares of common stock, par value $ 0.001 per share (the «Common Stock») of Avigen, Inc., a Delaware corporation (the «Company»), in exchange for the Consideration (as defined below) pursuant to letters sent by the Offeror to the Company dated December 22, 2008 and February 9, 2009 (the «Letters»), which letters are contained in the Offeror's Current Reports on Form 8 - K filed with the Securities and Exchange Commission (the «SEC») on December 23, 2008 and February 9, 2009, respectcommon stock, par value $ 0.001 per share (the «Common Stock») of Avigen, Inc., a Delaware corporation (the «Company»), in exchange for the Consideration (as defined below) pursuant to letters sent by the Offeror to the Company dated December 22, 2008 and February 9, 2009 (the «Letters»), which letters are contained in the Offeror's Current Reports on Form 8 - K filed with the Securities and Exchange Commission (the «SEC») on December 23, 2008 and February 9, 2009, respectistock, par value $ 0.001 per share (the «Common Stock») of Avigen, Inc., a Delaware corporation (the «Company»), in exchange for the Consideration (as defined below) pursuant to letters sent by the Offeror to the Company dated December 22, 2008 and February 9, 2009 (the «Letters»), which letters are contained in the Offeror's Current Reports on Form 8 - K filed with the Securities and Exchange Commission (the «SEC») on December 23, 2008 and February 9, 2009, respectCommon Stock») of Avigen, Inc., a Delaware corporation (the «Company»), in exchange for the Consideration (as defined below) pursuant to letters sent by the Offeror to the Company dated December 22, 2008 and February 9, 2009 (the «Letters»), which letters are contained in the Offeror's Current Reports on Form 8 - K filed with the Securities and Exchange Commission (the «SEC») on December 23, 2008 and February 9, 2009, respectiStock») of Avigen, Inc., a Delaware corporation (the «Company»), in exchange for the Consideration (as defined below) pursuant to letters sent by the Offeror to the Company dated December 22, 2008 and February 9, 2009 (the «Letters»), which letters are contained in the Offeror's Current Reports on Form 8 - K filed with the Securities and Exchange Commission (the «SEC») on December 23, 2008 and February 9, 2009, respectively.